Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Stem Cell Mobilization in Lymphoma
NCT05961410Phase 2Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Aug 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by National Taiwan University Hospital. Primary endpoint: Number of harvested CD34+ cells in first stem cell harvest day at 1 day. Started Aug 2023; status: recruiting.
02
Drugs
eltrombopag
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05961410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05961410.